Quarterly ResultAug 4, 2026, 07:22 AM
Certara Reports Q2 Net Loss of $55.27M; Divests Medical Writing Business
AI Summary
Certara reported a significant net loss for the second quarter and first half of 2026, primarily driven by losses from discontinued operations. The company completed the divestment of its Regulatory and Medical Writing business on May 8, 2026. While revenue from continuing operations saw a slight increase, operating results for continuing operations also turned to a loss.
Key Highlights
- Completed divestment of Regulatory and Medical Writing business on May 8, 2026.
- Q2 2026 net loss attributable to common stockholders: $55.27 million.
- Q2 2026 basic loss per share: $0.36.
- Q2 2026 revenue from continuing operations: $93.27 million.
- Six-month net loss attributable to common stockholders: $64.03 million.
- Six-month basic loss per share: $0.41.
- Six-month cash used in common stock repurchase program: $57.39 million.
- Cash provided by investing activities from discontinued operations: $69.44 million.
Price Impact
More from CERT